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Background: The peroxisome proliferator-activated receptor gamma (PPARG), Pro12Ala and the insulin receptor
substrate (IRS1), Gly972Arg confer opposite effects on insulin resistance and type 2 diabetes mellitus (T2DM). We
investigated the independent and joint effects of PPARG Pro12Ala and IRS1 Gly972Arg on markers of insulin
resistance and T2DM in an African population with elevated risk of T2DM. In all 787 (176 men) mixed-ancestry
adults from the Bellville-South community in Cape Town were genotyped for PPARG Pro12Ala and IRS1 Gly972Arg
by two independent laboratories. Glucose tolerance status and insulin resistance/sensitivity were assessed.
Results: Genotype frequencies were 10.4% (PPARG Pro12Ala) and 7.7% (IRS1 Gly972Arg). Alone, none of the
polymorphisms predicted prevalent T2DM, but in regression models containing both alleles and their interaction
term, PPARG Pro12 conferred a 64% higher risk of T2DM. Furthermore PPARG Pro12 was positively associated in
adjusted linear regressions with increased 2-hour post-load insulin in non-diabetic but not in diabetic participants.
Conclusion: The PPARG Pro12 is associated with insulin resistance and this polymorphism interacts with IRS1
Gly972Arg, to increase the risk of T2DM in the mixed-ancestry population of South Africa. Our findings require
replication in a larger study before any generalisation and possible application for risk stratification.
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Insulin resistance is a fundamental etiopathogenic factor
for type 2 diabetes and is also linked to a wide array of
other pathophysiological derangements including hyper-
tension, hyperlipidemia, atherosclerosis and polycystic
ovarian disease [1]. The gold standard method for as-
sessing insulin resistance/sensitivity is the euglycemic
hyperinsulinemic clamp [2,3], however, this technique is
cumbersome, particularly for large scale epidemiological
studies. Thus relatively simple, non-invasive alternative
techniques validated against the euglycemic clamp have* Correspondence: matshat@cput.ac.za
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stated.been proposed. The homeostatic model assessment of
insulin resistance (HOMA-IR) [4] and quantitative insu-
lin-sensitivity check index (QUICKI) [5] methods are
commonly used for insulin resistance and insulin sensi-
tivity, respectively. It is well recognised that the develop-
ment of insulin resistance and type 2 diabetes is in part
modulated by the gene-gene interaction processes.
The peroxisome proliferator-activated receptor gamma
(PPARG) and the insulin receptor substrate (IRS1) genes
have been shown to be associated with both insulin re-
sistance and type 2 diabetes [6-11]. The PPARG is a
member of the super family of nuclear receptors re-
ported to be involved in the regulation of adipocyte dif-
ferentiation [12], lipid metabolism and insulin sensitivity
[6]. Several variants in the PPARG gene have beenral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Vergotine et al. BMC Genetics 2014, 15:10 Page 2 of 8
http://www.biomedcentral.com/1471-2156/15/10identified, with the most prevalent variant being the
Pro12Ala polymorphism resulting from the CCA-to-
GCA missense mutation in codon 12 of exon B that en-
codes the NH2 terminal residue [13-15]. The proline
which is the common allele is associated with increased
risk whilst the alanine confers a protective effect against
insulin resistance and type 2 diabetes [9,16-20]. In con-
trast, the glycine to arginine substitution in codon 972
(Gly972Arg) of the IRS1 gene is associated with an in-
creased risk of insulin resistance [21]. In view of the
above, we investigated the independent and joint effects
of PPARG Pro12Ala and IRS1 Gly972Arg on markers of
insulin resistance and type 2 diabetes in the mixed-
ancestry population of South Africa, a population with
elevated risk of type 2 diabetes.
Results
Clinical characteristics of participants overall and ac-
cording to type 2 diabetes status are summarized in
Table 1 indicating that two hundred and twelve par-
ticipants (26.9%) had type 2 diabetes. As expected, the
distribution of the level of insulin resistance/sensitivity
indicators was significantly different between the two
groups (all p < 0.0001, except for glucose/insulin ratio
(p = 0.016). Furthermore, compared with non-diabetic
participants, those with type 2 diabetes had signi-
ficantly higher levels of adipometric variables (all p ≤
0.028), systolic blood pressure (p < 0.0001), triglycerides
(p < 0.0001), GGT and CRP (both p < 0.0001), whilst eGFR
(p = 0.015) and HDL cholesterol (p = 0.0001) were signi-
ficantly lower.
IRS1 Gly972Arg and PPARG Pro12Ala variants were
in HWE (p > 0.05) and their genotype and allele distribu-
tion by type 2 diabetes status is summarized in Table 2.
Overall, the genotype distributions of the two poly-
morphisms did not differ significantly between the two
groups. However the allele G of PPARG (12Ala) was
significantly more frequent in the diabetic subjects than
in the non-diabetic subjects (13.7% vs. 9.3%, p = 0.012).
The genotype frequencies, PPARG Pro12Ala and IRS1
Gly972Arg were 10.4% and 7.7%, respectively.
In generalised linear regression analyses adjusted for
age, sex and type 2 diabetes (Table 3), the IRS1 allele A
(972Arg) was associated with none of the marker of gly-
caemia, insulin resistance or insulin sensitivity, both
overall and in participants with and without type 2 dia-
betes taken separately; with no evidence of significant
statistical interaction by type 2 diabetes status (all in-
teraction p ≥ 0.330), except for 2 hour glucose where
the effect size appeared to be greater although non-
significantly among diabetic than non-diabetic partici-
pants (interaction p = 0.038). In similar generalised linear
regression models (Table 3) the PPARG allele C (Pro12)
increased 2 hour insulin levels in the overall cohort (p =0.009) and in the non-diabetic group only (p = 0.0003)
after stratification by type 2 diabetes status, with a sig-
nificant statistical interaction (p = 0.017). Otherwise, the
PPARG allele C was not significantly associated with the
marker of glycaemia, insulin resistance or insulin sensi-
tivity, both overall and by type 2 diabetes status; with
evidence however that the effect on 2-hour glucose if
any, could be more pronounced in people with type 2
diabetes (p-value = 0.002 for the PPARG allele C type 2
diabetes interaction). The main effects for IRS1 and
PPARG did not change significantly when they were ad-
justed for each other in regression models with or with-
out further adjustment for their interaction term.
In logistic regression models adjusted for each other,
or containing age and sex, with and without further ad-
justment for markers of insulin resistance/sensitivity
(Table 4), neither the IRS1 allele A, nor the PPARG was
significantly associated with prevalent type 2 diabetes.
However, in the model containing both alleles and their
interaction term, the PPARG allele C was associated with
higher risk of prevalent type 2 diabetes, odds ratio (95%
confidence interval) 1.64 (1.00-2.64).
Discussion
The mixed ancestry population of South Africa has one
of the highest prevalence of type 2 diabetes in South Af-
rica and sub-Saharan Africa at large [22], however, gen-
etic abnormalities that can fully account for this have
not been identified. In this study, we show that PPARG
Pro12 is significantly associated with insulin resistance
and type 2 diabetes in this population. We observed that
neither IRS1 972Arg allele nor PPARG 12Ala were asso-
ciated with type 2 diabetes or insulin resistance/sensitiv-
ity, but in a model containing both the alleles and their
interaction term, the presence of the PPARG Pro12 con-
ferred a 64% risk of prevalent type 2 diabetes. Further-
more the PPARG Pro12 was associated with increased
levels of 2 hour post-OGTT insulin. Overall, our findings
convincingly demonstrate that PPARG Pro12Ala –IRS1
Gly972Arg interactions, PPARG Pro12 and susceptibility
to environmental factors might modulate the relationship
between insulin resistance and type 2 diabetes in this
population.
The gene-gene interaction between IRS1 Gly972Arg
and PPARG Pro12Ala is of interest because the two
polymorphisms exert opposite effects on type 2 diabetes
predispositions. The Gly972Arg is a functional poly-
morphism reported to impair insulin signaling in trans-
fected cell lines and in human cells carrying the variant
[23-25]. Although individuals carrying the Gly972Arg
are reported to have a 25% increased risk for developing
diabetes [10], genome wide association (GWAS) studies
involving subjects of European descent found no associ-
ation between IRS1 and type 2 diabetes [26,27]. On the
Table 1 General characteristics of the overall population and by diabetic status
Variable Non-diabetic Diabetic P-value Overall
Number 575 212 787
Gender, male n (%) 131 (22.8) 45 (21.2) 0.642 176
Mean age, year (SD) 51.3 (15.5) 59.3 (13.4) <0.0001 53.5 (15.4)
Mean systolic blood pressure, mmHg (SD) 123 (19) 131 (23) <0.0001 124 (21)
Mean diastolic blood pressure, mmHg (SD) 75 (12) 78 (15) 0.035 76 (13)
Hypertension, n (%) 306 (53.2) 138 (65.1) 0.003 444
Mean body mass index, kg/m2 (SD) 29.1 (7.1) 31.7 (7.2) <0.0001 29.8 (7.2)
Mean waist circumference, cm (SD) 95 (15) 102 (14) <0.0001 97 (16)
Mean hip circumference, cm (SD) 109 (14) 111 (15) 0.028 109 (14)
Mean waist/hip ratio, (SD) 0.87 (0.10) 0.92 (0.09) <0.0001 0.88 (0.10)
Mean HbA1c, % (SD) 5.7 (0.4) 7.8 (2.1) <0.0001 6.3 (1.5)
Mean HbA1c, mmol/mol (SD) 39 (4.4) 62 (23) <0.0001 45 (16.4)
Mean fasting blood glucose, mmol/l (SD) 5.1 (0.7) 9.8 (4.4) <0.0001 6.4 (3.1)
Mean 2 h glucose, mmol/l (SD) 6.4 (1.6) 13.4 (5.3) <0.0001 7.3 (3.5)
Mean eGFR, ml/min (SD) 76.0 (21.1) 71.2 (25.2) 0.015 74.7 (22.4)
Mean triglycerides, mmol/l (SD) 1.4 (0.9) 1.7 (0.9) <0.0001 1.5 (0.9)
Mean HDL cholesterol, mmol/l (SD) 1.3 (0.4) 1.2 (0.3) 0.0001 1.3 (0.4)
Mean LDL cholesterol, mmol/l (SD) 3.6 (1.0) 3.7 (1.1) 0.191 3.6 (1.0)
Mean total cholesterol, mmol/l (SD) 5.5 (1.2) 5.7 (1.3) 0.070 5.6 (1.2)
Median GGT (25th-75th percentiles) 26 [18-39] 31 [23-39] <0.0001 27 [19-42]
Median CRP (25th-75th percentiles) 3.4 [0.8-8.4] 5.2 [1.9-10.8] <0.0001 4.0 [1.1-9.4]
Median insulin mmol/l (25th-75th percentiles) 6.9 [3.3-12.5] 9.2 [3.7-16.6] 0.0009 7.5 [3.3-13.5]
Median 2 h insulin mmol/l (25th-75th percentiles) 35.3 [19.2-64.5] 58.9 [22.1-115.2] 0.0009 36.8 [19.5-72.7]
Median glucose/insulin (25th-75th percentiles) 0.72 [0.42-1.51] 0.88 [0.50-2.30] 0.016 0.75 [0.43-1.68]
Median HOMA-IR (25th-75th percentiles) 1.6 [0.7-2.9] 3.5 [1.5-6.7] <0.0001 1.9 [0.8-3.7]
Median HOMA-B% (25th-75th percentiles) 90.0 [41.1-160.0] 40.7 [12.4-77.8] <0.0001 71.2 [28.6-44.9]
Median QUICKI (25th-75th percentiles) 0.15 [0.14-0.18] 0.14 [0.13-0.15] <0.0001 0.15 [0.14-0.17]
Median FIRI (25th-75th percentiles) 1.4 [0.6-2.6] 3.1 [1.3-6.0] <0.0001 1.8 [0.7-3.3]
Median 1/HOMA-IR (25th-75th percentiles) 0.64 [0.34-1.49] 0.29 [0.15-0.66] <0.0001 0.54 [0.27-1.26]
CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; FIRI, fasting insulin resistance index; GGT, γ-glutamyltransferase; HbA1c, glycated haemoglobin; HDL,
High Density Lipoproteins; HOMA-β%, functional β-cells; HOMA-IR, homeostatic model assessment of insulin resistance; LDL, Low Density Lipoproteins; QUICKI, the
quantitative insulin-sensitivity check index; SD, standard deviation.
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has been associated with a reduced risk of type 2 dia-
betes and insulin resistance [9,16-20]. As such, the poly-
morphisms of the IRS1 and PPARG genes have been
shown to interact and elevate insulin sensitivity. This
was evident in a study done by Stumvoll et al., [28]
where the authors showed that insulin sensitivity was sig-
nificantly greater in subjects with X/Ala (PPARγ2) + X/Arg
(IRS1 972) than in subjects with Pro/Pro (PPARγ2) + X/Arg
(IRS1) while no differences were observed in X/Ala
(PPARγ2) +Gly/Gly (IRS1 972) and Pro/Pro (PPARγ2) +
Gly/Gly (IRS1 972) carriers [28]. Similarly, the interaction
between the two polymorphisms has been associated with
higher adiponectin levels and the greatest increase was
found in subjects who were homozygous for both PPARGalanine (Ala12Ala) and IRS1 glycine (Gly972Gly) [29].
Adiponectin is secreted by the adipose tissue and is in-
versely associated with obesity, insulin resistance, type 2
diabetes and cardiovascular disease [30,31]. Taken to-
gether these reports including ours confirm the com-
bined effect of the two SNPs on insulin resistance and
type 2 diabetes.
Several epidemiological studies have demonstrated
that PPARG Pro12Ala is associated with insulin sensitiv-
ity and diabetes mellitus [6-9]. In the Human Genome
Epidemiology (HuGE) meta-analysis involving 32 849
type 2 diabetes cases and 47 456 controls, the Pro12Ala
was associated with a 14% lower risk for developing type
2 diabetes [8]. However, other investigators have failed
to demonstrate an association between Pro12Ala and
Table 3 Generalized linear regression models showing the eff
Non- diabetic
Allele Phenotype Effects size 95% CI
IRS1 A Fasting glucose 0.09 −0.11 to 0.30 0
2 h glucose 0.08 −0.36 to 0.51 0
HbA1c 0.02 −0.10 to 0.14 0
Fasting insulin −1.02 −3.76 to 1.71 0
2 h insulin 1.62 −15.50 to 18.75 0
Glucose/insulin −0.14 −2.26 to 1.97 0
HOMA-IR −0.22 −0.87 to 0.42 0
QUICKI 0.002 −0.015 to 0.018 0
FIRI −0.20 −0.78 to 0.38 0
PPARG C Fasting glucose −0.06 −0.26 to 0.13 0
2 h glucose −0.02 −0.44 to 0.41 0
HbA1c 0.07 −0.04 to 0.19 0
Fasting insulin −0.56 −3.21 to 2.09 0
2 h insulin 34.0 15.9 to 52.2 0.0
Glucose/insulin −0.21 −2.26 to 1.83 0
HOMA-IR −0.12 0.74 to 0.51 0
QUICKI 0.0001 −0.015 to 0.016 0
FIRI −0.10 −0.67 to 0.46 0
Models are adjusted for age, sex and diabetes. FIRI, fasting insulin resistance index;
Substrate Receptor 1; PPARG, Peroxisome Proliferator-Activated Receptor Gamma; Q
Table 2 Genotype distributions, minor allele frequencies
and unadjusted p-values for comparing genotype
distribution according to diabetes status, additive allelic
effects between diabetes groups
Non-diabetic Diabetic p-value Overall
N 575 212 787
IRS1
G/G, n (%) 526 (91.5) 199 (93.9) 0.485 725 (92.1)
G/A, n (%) 48 (8.3) 13 (6.1) 61 (7.7)
A/A, n (%) 1 (0.2) 0 (0) 1 (0.1))
A, n (%) 50 (4.4) 13 (3.1) 0.131 63 (4.0)
HWE (p-value) >0.999 >0.999 >0.999
PPARG
C/C, n (%) 521 (90.6) 183 (86.3) 0.161 704 (89.4)
C/G, n (%) 53 (9.2) 29 (13.7) 82 (10.4)
G/G, n (%) 1 (0.2) 0 (0) 1 (0.1)
G, n (%) 55 (4.9) 29 (6.8) 0.012 84 (5.3)
HWE (p-value) >0.999 0.605 0.719
HWE, Hardy-Weinberg Equilibrium (HWE p-values are from exact tests).
IRS1, Insulin Substrate Receptor 1; PPARG, Peroxisome Proliferator-Activated
Receptor Gamma.
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assessing insulin resistance/sensitivity, the euglycemic
hyperinsulinemic clamp [32,33]. The differences between
studies have been attributed to body mass index and
ethnic differences [7,8]. The frequency of the 12Ala has
been reported to be more frequent in Caucasians than in
Asian populations [8], but conferred significantly greater
protection against type 2 diabetes among Asians than
Caucasians (35% vs. 15%) [7]. However, when the au-
thors adjusted for body mass index the differences were
no longer significant [7]. In our study, the 10.4% fre-
quency of Pro12Ala polymorphism is comparable to that
found in Caucasians and the Pro12 was strongly associ-
ated with an increased 2 hour post-OGTT insulin levels
in non-diabetic subjects. Our results further add to the
growing body of evidence on the association of PPARG
Pro12Ala, insulin resistance and subsequent type 2 dia-
betes. Herein we investigated a heterogeneous popula-
tion, with 32-43% Khoisan, 20 – 36% Bantu-speaking
African, 21 – 28% European and 9 – 11% Asian ancestry
[34]. Our present findings require replication in a larger
study involving other homogenous population before
they can be considered as established in Africa.
The strengths of the present study include the use of
both fasting and OGTT derived indices for assessing
type 2 diabetes and insulin resistance. OGTT derived in-
dices have been found to be of superior predictive powerects of genes on markers of insulin resistance/sensitivity
Diabetic p interaction
p Effects size 95% CI p
.372 −0.53 −2.96 to 1.90 0.668 0.330
.723 2.33 −2.09 to 6.75 0.304 0.038
.746 0.13 −1.04 to 1.31 0.823 0.853
.463 −3.27 −20.75 to 14.21 0.714 0.690
.853 2.36 −63.13 to 67.86 0.944 0.944
.894 0.30 −8.40 to 9.00 0.946 0.896
.498 −2.03 −9.96 to 5.91 0.617 0.448
.857 −0.001 −0.025 to 0.022 0.903 0.877
.480 −1.82 −8.97 to 5.31 0.617 0.448
.528 0.003 −1.71 to 1.72 0.995 0.970
.933 −2.46 −5.68 to 0.76 0.137 0.002
.216 −0.18 1.02 to 0.65 0.663 0.362
.617 −5.72 −18.00 to 6.57 0.363 0.283
003 −14.4 −64.7 to 35.8 0.575 0.017
.840 −2.62 −8.82 to 3.37 0.407 0.307
.714 −2.31 −7.89 to 3.27 0.417 0.299
.924 −0.007 −0.024 to 0.009 0.377 0.481
.714 −2.08 −7.10 to 2.94 0.417 0.299
HOMA-IR, homeostatic model assessment of insulin resistance; IRS1, Insulin
UICKI, the quantitative insulin-sensitivity check index.
Table 4 Odds ratio and 95% confidence intervals from
logistic regression for the prediction of diabetes
Allele Covariates OR (95% CI) P
IRS1 A Gene alone 0.69 (0.36-1.25) 0.250
Sex, age 0.67 (0.34-1.24) 0.228
Sex, age, insulin 0.70 (0.35-1.31) 0.290
Sex, age, 2 h insulin 0.76 (0.28-1.76) 0.562
Sex, age, HOMA-IR 0.72 (0.35-1.39) 0.347
Sex, age, QUICKI 0.70 (0.35-1.31) 0.285
Sex, age, FIRI 0.72 (0.35-1.39) 0.347
Sex, age, glucose/insulin 0.67 (0.34-1.27) 0.224
PPARG 0.69 (0.36-1.25) 0.248
PPARG, IRS1*PPARG 0.85 (0.43-1.57) 0.613
PPARG C Gene alone 1.48 (0.91-2.36) 0.104
Sex, age 1.40 (0.85-2.28) 0.176
Sex, age, fasting insulin 1.49 (0.90-2.45) 0.116
Sex, age, 2 h insulin 1.24 (0.56-2.53) 0.571
Sex, age, HOMA-IR 1.51 (0.88-2.56) 0.131
Sex, age, QUICKI 1.40 (0.83-2.32) 0.198
Sex, age, FIRI 1.51 (0.88-2.56) 0.131
Sex, age, glucose/insulin 1.41 (0.85-2.51) 0.174
IRS1 1.48 (0.91-2.37) 0.103
IRS1, IRS1*PPARG 1.64 (1.00-2.64) 0.046
*, interaction; FIRI, fasting insulin resistance index; HOMA-IR, homeostatic
model assessment of insulin resistance; IRS1, Insulin Substrate Receptor 1;
PPARG, Peroxisome Proliferator-Activated Receptor Gamma; QUICKI, the
quantitative insulin-sensitivity check index.
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glucose-insulin interaction into account [35]. Further-
more, we made use of two independent laboratories to
genotype our study population. The major limitation of
our study is the statistical power of the study which was
limited by the small sample size and the examination of
gene-gene interaction effects reduced the sample further.
In addition, we did not adjust for population stratifica-
tion. Potential population stratification in unrelated sam-
ple may cause spurious positive or negative associations
in population-based association studies [36]. To minim-
ise this type of confounding in association studies, sev-
eral approaches have been suggested that utilise specific
informative markers and loci to model ancestral dif-
ferences between cases and controls and subsequently
correct allele frequency variations at candidate loci in
populations. However, markers suitable for mapping dis-
ease genes or correcting for population stratification in
the mixed ancestry are not yet available. Lastly, the na-
ture of this study is cross-sectional with high female to
male participation, the latter being a common trend in
South African population studies.Conclusion
Despite the above mentioned limitations, our results
provide the first preliminary evidence for genetic predis-
position to insulin resistance and subsequent type 2 dia-
betes in an African population with a high prevalence of
type 2 diabetes. In conclusion, the PPARG Pro12 is as-
sociated with insulin resistance and this polymorphism
interacts with an additional unfavourable genetic poly-
morphism, IRS1 Gly972Arg, to increase the risk of
type 2 diabetes in the mixed ancestry population of
South Africa.
Methods
Study setting and population
The study setting, survey design and procedures have
been described in details elsewhere [22,37]. Briefly, par-
ticipants were members of a cohort study conducted in
Bellville-South, Cape Town. According to the 2011
South African population census, the population is pre-
dominantly of mixed ancestry (76%) followed by black
Africans (18.5%) and Caucasian and Asians making only
1.5%. Eligible participants were invited to take part in a
community based survey from January 2008 to March
2009 (Cohort 1), and January 2011 to November 2011
(Cohort 2). The study was approved by the Research
Ethics Committees of the University of Stellenbosch
(HREC Ref No: N09/05/146) and Cape Peninsula Uni-
versity of Technology, Faculty of Health and Wellness
Sciences ethics committee (Reference Number: CPUT/
HW-REC 2008/002 and CPUT/HW-REC 2010). The
study was conducted according to the Code of Ethics
of the World Medical Association (Declaration of
Helsinki). All participants signed written informed
consent after all the procedures were fully explained in
the language of their choice.
Clinical data
All consenting participants received a standardized inter-
view and physical examination during which blood pressure
was measured according to the World Health Organisation
(WHO) guidelines [38] using a semi-automated digital
blood pressure monitor (Rossmax PA, USA) on the
right arm in a sitting position. Other clinical measure-
ments included the body weight, height, waist and hip
circumferences. Weight (to the nearest 0.1 kg) was de-
termined in a subject wearing light clothing and without
shoes and socks, using a Sunbeam EB710 digital bath-
room scale, which was calibrated and standardized
using a weight of known mass. Waist circumference was
measured using a non-elastic tape at the level of the
narrowest part of the torso, as seen from the anterior
view. The hip circumference was also measured using
a non-elastic tape around the widest portion of the but-
tocks. All anthropometric measurements were performed
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pants with no history of doctor diagnosed diabetes melli-
tus underwent a 75 g oral glucose tolerance test (OGTT)
as recommended by the WHO [39].
Laboratory measurements
Blood samples were collected after an overnight fast and
processed for further biochemical analysis. Plasma glu-
cose was measured by enzymatic hexokinase method
(Cobas 6000, Roche Diagnostics, Germany) and glycated
haemoglobin (HbA1c) by turbidimetric inhibition im-
munoassay (Cobas 6000, Roche Diagnostics, Germany)
this being a National Glycohaemoglobin Standardisation
Programme (NGSP) certified method. Creatinine levels
were measured using the standardized creatinine assay
(Cobas 6000, Roche Diagnostics, Germany). Total chol-
esterol (TC), high density lipoprotein cholesterol (HDL-
c), triglycerides (TG) and γ-glutamyltransferase (GGT)
were estimated by enzymatic colorimetric methods (Cobas
6000, Roche Diagnostics). Low density lipoprotein choles-
terol (LDL-c) was calculated using Friedewald’s formula
[40]. Insulin was determined by a microparticle enzyme
immunoassay (Axsym, Abbot). C-reactive protein (CRP)
was measured by a high-sensitivity CRP assay, based on
the highly sensitive Near Infrared Particle Immunoassay
rate methodology (Immage® Immunochemistry System;
Beckman Coulter), with a lower limit of detection of
0.2 mg/L.
SNP genotyping
Genomic DNA was extracted from whole blood samples
collected in an EDTA tube. Single nucleotide polymor-
phisms (SNPs) in the IRS1 (rs1801278, G > A) [Gene-
Bank: NM_005544], and PPARG (rs1801282, C > G)
[GeneBank: NM_015869] were genotyped using high
throughput real-time polymerase chain reaction (RT-
PCR) in two independent laboratories (Centre for
Proteomic and Genomic Research Institute of infec-
tious Diseases and Molecular Medicine, Faculty of
Health Sciences, University of Cape Town and Obesity
and Chronic Diseases of Lifestyle, Faculty of Health &
Wellness Sciences, Cape Peninsula University of Tech-
nology) on the ABI Prism 7900HT platform(Applied
Biosystems, USA) and a BioRad Optica (BioRad, USA)
using Taqman genotyping assay (Applied Biosystems,
USA). Direct sequencing was used to for analytical val-
idation of high throughput genotyping against direct
sequencing as the gold standard
Definitions and calculations
Body mass index (BMI) was calculated as weight per
square meter (kg/m2) and waist-hip-ratio (WHR) as
waist/hip circumferences (cm). Type 2 diabetes status
was based on a history of doctor-diagnosis, a fastingplasma glucose ≥7.0 mmol/l and/or a 2-hour post-
OGTT plasma glucose ≥11.1 mmol/l. The homeostatic
model assessment of insulin resistance (HOMA-IR) was
calculated according to the formula: HOMA-IR = [fas-
ting insulin concentration (mIU/L) × fasting plasma glu-
cose (mmol/L]/22.5; while functional β-cells (HOMA-B%)
were estimated using the formula: 20 × fasting insulin
(μIU/ml)/fasting glucose (mmol/ml) − 3.5. The fasting
insulin resistance index (FIRI) was calculated with the
formula: [fasting insulin (μU/ml) × fasting glucose (mM)]/
25 and the quantitative insulin-sensitivity check index
(QUICKI) as: 1/[log (fasting insulin (μU/ml)) × log (fast-
ing glucose (mg/dl)]. Glomerular filtration rate (GFR)
was estimated by the 4-variable Modification of Diet in
Renal Disease (MDRD) equation [41,42] applicable to
standardised serum creatinine values.Statistical analysis
Of the 946 participants who took part in the survey, 941
consented for genetic studies. Among the latter, 154
were excluded for missing data on the genetic variables.
Therefore, 787 had valid data for the current analyses.
General characteristics of the study group are summa-
rized as count and percentage for dichotomous traits,
mean and standard deviation (SD) or median and 25th-
75th percentiles for quantitative traits. Traits were log-
transformed to approximate normality, where necessary,
prior to analysis. SNPs were tested for departure from
Hardy-Weinberg Equilibrium (HWE) expectation via a
chi square goodness of fit test. Linear regression models
were used for the analysis of quantitative traits and lo-
gistic regression models for dichotomous traits, always
assuming additive models for the SNPs. Using linear and
logistic models enabled us to adjust all analyses for
known confounders as specified everywhere in the re-
sults. We investigated the additive allelic association of
each SNP with each trait, overall and according to type
2 diabetes status, and tested for heterogeneity by adding
the interaction term of type 2 diabetes and each SNP to
a model that contained the main effects of type 2 dia-
betes and the relevant SNP. Results corresponding to p-
values below 5% are described as significant. We did not
adjust for multiple testing. All analyses used the statis-
tical package R (version 3.0.0 [2013-04-03], The R Foun-
dation for statistical computing, Vienna, Austria).Authors’ contribution
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